24.02.2005 23:00:00
|
Millipore Forms New Bioscience Division
Business Editors/Health Editors
BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 24, 2005--Millipore Corporation (NYSE:MIL) announced that it has formed a new Bioscience Division that will focus on life science research and general laboratory applications of Millipore products and services. The new division combines Millipore's Life Sciences Division and Laboratory Water Division which essentially served the same customer base. The intent is to provide more organizational clarity, improve sales effectiveness, better serve customers, and focus R&D investments in the laboratory area.
Dominique Baly, who has served as president of the Laboratory Water Division, will lead the new organization.
About Millipore
Millipore is a multinational, high technology company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries. For more information about Millipore visit www.millipore.com.
--30--GK/bo*
CONTACT: Millipore Corporation Investor Contact Geoffrey Helliwell, 978-715-1041 or 800-225-3384 Geoffrey_Helliwell@Millipore.com or Media Contact Thomas Anderson, 978-715-1043 or 800-225-3384 Thomas_Anderson@Millipore.com
KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL DEVICES BIOTECHNOLOGY PRODUCT SOURCE: Millipore Corporation
Copyright Business Wire 2005

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck KGaAmehr Nachrichten
26.02.25 |
Aufschläge in Frankfurt: LUS-DAX zum Ende des Mittwochshandels mit Gewinnen (finanzen.at) | |
26.02.25 |
Börse Frankfurt: DAX verbucht zum Ende des Mittwochshandels Gewinne (finanzen.at) | |
26.02.25 |
Gewinne in Frankfurt: Börsianer lassen LUS-DAX am Nachmittag steigen (finanzen.at) | |
26.02.25 |
Gewinne in Frankfurt: DAX notiert am Nachmittag im Plus (finanzen.at) | |
26.02.25 |
XETRA-Handel: DAX verbucht am Mittag Zuschläge (finanzen.at) | |
26.02.25 |
Starker Wochentag in Frankfurt: LUS-DAX mittags in der Gewinnzone (finanzen.at) | |
24.02.25 |
DAX 40-Papier Merck-Aktie: So viel Gewinn hätte ein Merck-Investment von vor 5 Jahren abgeworfen (finanzen.at) | |
19.02.25 |
Schwache Performance in Frankfurt: DAX schwächelt am Mittwochmittag (finanzen.at) |
Analysen zu Merck KGaAmehr Analysen
16:32 | Merck Buy | UBS AG | |
19.02.25 | Merck Buy | Goldman Sachs Group Inc. | |
18.02.25 | Merck Overweight | JP Morgan Chase & Co. | |
10.02.25 | Merck Overweight | JP Morgan Chase & Co. | |
10.02.25 | Merck Buy | Goldman Sachs Group Inc. |
Aktien in diesem Artikel
Merck KGaA | 134,45 | -1,14% |
|
Indizes in diesem Artikel
S&P 500 | 5 861,57 | -1,59% |